Determinants of clinical outcome in high grade serous ovarian cancer

被引：0
|
作者：
Bowtell, David D. L. [1 ]
Cown, Prue [1 ]
Etemadmoghadam, Dariush [1 ]
Alsop, Kathryn [1 ]
George, Joshy [1 ]
de Fazaio, Anna [2 ]
Mitchell, Gillian [1 ]
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Westmead Inst Canc Reseach, Sydney, NSW, Australia
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-5082
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5082
引用
收藏
页数：1
相关论文
共 50 条
  • [41] HRD and disease distribution in high grade serous ovarian cancer
    Gauroy, Elodie
    Martinez, Alejandra
    Bataillon, Guillaume
    Ricotta, Giulio
    Ferron, Gwenael
    Navarro Navarro, Anne Sophie
    Betrian, Sarah
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A408 - A408
  • [42] Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma
    Milea, Anca
    George, Sophia H. L.
    Matevski, Donco
    Jiang, Haiyan
    Madunic, Mary
    Berman, Hal K.
    Gauthier, Mona L.
    Gallie, Brenda
    Shaw, Patricia A.
    MODERN PATHOLOGY, 2014, 27 (07) : 991 - 1001
  • [43] Molecular Profiling and Clinical Outcome of High-Grade Serous Ovarian Cancer Presenting with Low- versus High-Volume Ascites
    Feigenberg, Tomer
    Clarke, Blaise
    Virtanen, Carl
    Plotkin, Anna
    Letarte, Michelle
    Rosen, Barry
    Bernardini, Marcus Q.
    Kollara, Alexandra
    Brown, Theodore J.
    Murphy, K. Joan
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [44] Increased STAT1 Expression in High Grade Serous Ovarian Cancer Is Associated With a Better Outcome
    Josahkian, Juliana A.
    Saggioro, Fabiano Pinto
    Vidotto, Thiago
    Ventura, Henrique Torres
    Candido dos Reis, Francisco Jose Prime
    de Sousa, Christiani Bisinoto
    Tiezzi, Daniel Guimaraes
    de Andrade, Jurandyr Moreira
    Koti, Madhuri
    Squire, Jeremy A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (03) : 459 - 465
  • [45] Homologous recombination status as a predictor for primary cytoreductive resection outcome in high grade serous ovarian cancer
    Hawarden, Amy
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A221 - A221
  • [46] Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer
    Buttarelli, Marianna
    De Donato, Marta
    Raspaglio, Giuseppina
    Babini, Gabriele
    Ciucci, Alessandra
    Martinelli, Enrica
    Baccaro, Pina
    Pasciuto, Tina
    Fagotti, Anna
    Scambia, Giovanni
    Gallo, Daniela
    CANCERS, 2020, 12 (04)
  • [47] Microenvironment cell populations are associated with clinical outcomes in high-grade serous ovarian cancer
    Watson, Rachel
    Linder, Katharine
    Gabrilovich, Sofia
    Ulmer, Keely
    Polio, Andrew
    Goodheart, Michael
    Bender, David
    Bosquet, Jesus Gonzalez
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S196 - S196
  • [48] Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer
    Kieffer, Yann
    Bonneau, Claire
    Popova, Tatiana
    Rouzier, Roman
    Stern, Marc-Henri
    Mechta-Grigoriou, Fatima
    FRONTIERS IN GENETICS, 2020, 11
  • [49] Investigating the Clinical Utility of a Targeted ctDNA Panel for High-grade Serous Ovarian Cancer
    Kelly, Tanya
    Ward, Mark
    Lewis, Faye
    Henderson, Brian
    Hurley, Sinead
    Norris, Lucy
    Martin, Cara
    Kamran, Waseem
    Abu Saadeh, Feras
    O'Leary, John
    O'Toole, Sharon
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1182 - S1182
  • [50] Association of fusion genes with clinical outcomes and survival in high-grade serous ovarian cancer
    Newtson, A. M.
    Reyes, H. D.
    Lyons, Y. A.
    Cardillo, N. D.
    Russo, D.
    Devor, E.
    Goodheart, M. J.
    Gonzalez-Bosquet, J.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 103 - 104
12345